Walking at Faster Speeds Linked to Reduction in Risk for Type 2 Diabetes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Nov. 29, 2023 -- Walking at faster speeds seems to be associated with a reduction in the risk for type 2 diabetes, according to a review published online Nov. 28 in the British Journal of Sports Medicine.
Ahmad Jayedi, Ph.D., from the University of Medical Sciences in Semnan, Iran, and colleagues examined the association between walking speed and the risk for type 2 diabetes in a systematic review and meta-analysis of 10 cohort studies.
The researchers found that for average/normal walking (3.2 to 4.8 km/hour), fairly brisk walking (4.8 to 6.4 km/hour), and brisk/striding walking (>6.4 km/hour), compared with easy/casual walking (<3.2 km/hour), the relative risks (95 percent confidence intervals) of type 2 diabetes were 0.85 (0.70 to 1.00), 0.76 (0.65 to 0.87), and 0.61 (0.49 to 0.73). Across subgroups based on adjustment for the total volume of physical activity and time spent walking per day, no significant or credible difference was seen. The risk for type 2 diabetes decreased significantly at a walking speed of 4 km/hour and greater according to a dose-response analysis.
"While current strategies to increase total walking time are beneficial, it may also be reasonable to encourage people to walk at faster speeds to further increase the health benefits of walking," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.